Treating depression with selective serotonin reuptake inhibitors: A practical approach

Mayo Clinic Proceedings

Volumn 76, Issue 7, 2001, Pages 739-744

  Sampson, Shirlene M ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; CYTOCHROME P450; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

DEPRESSION; DISEASE CLASSIFICATION; DRUG MONITORING; DRUG SAFETY; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INAPPROPRIATE VASOPRESSIN SECRETION; REVIEW; SEROTONIN SYNDROME; SEXUAL DYSFUNCTION; TREATMENT OUTCOME;

EID: 0034961677     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/76.7.739     Document Type: Review

References (16)

1. Blazer DG II. Mood disorders: epidemiology. In: Sadock BJ, Sadock VA, eds. Kaplan & Sadock's Comprehensive Textbook of Psychiatry. Vol 1. 7th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2000:1298-1308.
2. Frank E, Thase ME. Natural history and preventative treatment of recurrent mood disorders. Anna Rev Med. 1999;50:453-468.
3. Kupfer DJ. Research in affective disorders comes of age [editorial]. Am J Psychiatry. 1999;156:165-167.
4. Hall RC, Wise MG. The clinical and financial burden of mood disorders: cost and outcome. Psychosomatic s. 1995;36:S11-S18.
5. Gallo JJ, Rabins PV. Depression without sadness: alternative presentations of depression in late life. Am F am Physician. 1999;60: 820-826.
6. Bezchlibnyk-Butler KZ, Jeffries JJ, eds. Clinical Handbook of Psychotropic Drugs. 10th rev ed. Seattle, Wash: Hogrefe & Huber Publishers; 2000.
7. Roy-Byrne P, Post RM, Uhde TW, Porcu T, Davis D. The longitudinal course of recurrent affective illness: life chart data from research patients at the NIMH. Acta Psychiatr Scand Suppl. 1985; 317:1-34.
8. Woodrum ST, Brown CS. Management of SSRI-induced sexual dysfunction. Ann Pharmacother. 1998;32:1209-1215.
9. Arana GW, Rosenbaum JF. Handbook of Psychiatric Drug Therapy. 4th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2000.
10. Edwards JG, Anderson I. Systematic review and guide to selection of selective serotonin reuptake inhibitors [published correction appears in Drugs. 1999;58:1207-1209]. Drugs. 1999;57:507533.
11. Masand PS, Gupta S. Selective serotonin-reuptake inhibitors: an update. Harv Rev Psychiatry. 1999;7:69-84.
12. Misri S, Burgmann A, Kostaras D. Are SSRIs safe for pregnant and breastfeeding women? Can Fam Physician. 2000;46:626-628,631 633.
13. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med. 1996;335:1010-1015.
14. Koren G, Nulman I, Addis A. Outcome of children exposed in utero to fluoxetine: a critical review. Depress Anxiety. 1998;8(suppl 1):27-31.
15. Nulman I, Rovet J, Stewart DE, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med. 1997; 336:258-262.
16. Stowe ZN, Calhoun K, Ramsey C, Sadek N, Newport J. Mood disorders during pregnancy and lactation: defining issues of exposure and treatment. CNS Spectrums. 2001 ;6:156, 161-166.